Weihang Bao

TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.

TL;DR: The scheduled infliximab groups, particularly the 10 mg/kg group, had better CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ) responses than those in the episodic group.

TL;DR: Scheduled infliximab maintenance therapy resulted in more improvement in mucosal ulceration and in higher rates of mucosal healing, and there was a numerical trend for patients with better mucosal Healing to have a lower rate of Crohn's disease-related hospitalizations.

TL;DR: Responsibility to infliximab was not associated with the genetic variants in the CARD15 gene in either cohort and the subsequent negative findings in a two-cohort model exclude SNPs 8, 12 and 13 of the Card15 gene as predictors for therapeutic response to inflIXimab treatment.

TL;DR: Infliximab therapy provides substantially improved HRQL as measured by both the disease-specific IBDQ and the generic SF-36 and a maintenance regimen of either 5 mg/kg or 10 mg/ kg of infliximab is more effective than a single 5-mg/kg inflixIMab infusion in sustaining this benefit.